Sagimet Biosciences Inc. (SGMT)
Develops experimental drugs that block fat-making enzymes to treat liver disease, acne, and cancer.
$7.27-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago-11.9%
The outlook
Analysts are strongly bullish on SGMT, with an average price target implying significant upside from current levels. The stock is trading above both its 50- and 200-day moving averages, suggesting positive near-term momentum. It's positioned roughly midway through its 52-week range, with analyst sentiment notably optimistic.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range48% of the way from its 52-week low to high
Price targetAvg target +260% vs current price
Analyst price target
~12-month · 10 analysts$26.20average target+260.4% vs now
Now $7.27
Low $8.00High $49.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$448.9M
52-wk high
$10.27
52-wk low
$4.50
50-day avg
$7.09
200-day avg
$6.60
Trailing P/E
—